BriaCell Therapeutics Corp. 8-K

What Happened
BriaCell Therapeutics Corp. disclosed on June 26, 2026 (Item 7.01, Regulation FD) that its subsidiary, BriaPro Therapeutics Corp., filed unaudited condensed interim consolidated financial statements and management’s discussion and analysis (MD&A) for the three- and nine-month periods ended April 30, 2026. Those documents were filed with the British Columbia Securities Commission and the Alberta Securities Commission and are included as exhibits to the Form 8-K.

Key Details

• Filing date: June 26, 2026 (Form 8-K disclosure by BriaCell referencing the subsidiary filing).
• Reporting period: three- and nine-month periods ended April 30, 2026.
• Documents: unaudited condensed interim consolidated financial statements (Exhibit 99.1) and MD&A (Exhibit 99.2).
• The Form 8-K also includes the Inline XBRL cover page (Exhibit 104) and incorporates the exhibits by reference.

Why It Matters
This 8-K gives investors access to the latest interim financial results and management commentary for BriaPro, a material subsidiary of BriaCell. The MD&A can provide management’s view on recent operations, trends and risks; the interim statements contain the detailed numbers investors need to assess quarterly performance. The Form 8-K itself summarizes the disclosure but does not reproduce the financial figures—investors should review Exhibits 99.1 and 99.2 for the actual results and metrics.